Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease constitutes the most prevalent hereditary kidney disease, associated with high rates of morbidity leading eventually to end-stage renal disease. Tolvaptan is a selective vasopressin antagonist and has emerged as a promising therapeutic option for patients...

Descripción completa

Detalles Bibliográficos
Autor principal: Bellos, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254589/
https://www.ncbi.nlm.nih.gov/pubmed/34234441
http://dx.doi.org/10.2147/TCRM.S286952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254589/
https://www.ncbi.nlm.nih.gov/pubmed/34234441
http://dx.doi.org/10.2147/TCRM.S286952

Ejemplares similares